Skip to content
★ Sign in to follow
SW

Stephen West

Chairman
Roquefort Therapeutics plc
Insider activity · 24 months2 buys0 salesCumulative net flow
Total declarations
5
Company
1
▲ Purchases (5 ops.)
€87k
▼ Sales (0 ops.)
—

Latest filing published 07 Jul 2025 for Roquefort Therapeutics plc, €42k.

Filing timeline

BuySale
Stephen West

Insider track record

Disclosed buys
5
Disclosed sells
0
Signal history

Closed purchases

Market purchases
4

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Stephen West: trading record in brief

This profile gathers the share dealings of Stephen West in Roquefort Therapeutics plc. We count 5 filings; the first trade dates from 4 July 2022 and the latest from 4 July 2025.

No open-market sale appears; the market trades are 5 purchases worth €87k. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2025: 2 purchases and no sales on the market.

The median purchase comes to €17k. On 2 out of 5 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The latest filing, published on 7 July 2025, reports an open-market purchase of €42k in Roquefort Therapeutics plc. Half of the filings or more reach the RNS (LSE) feed on the day of the trade. The legal deadline for notifying a trade is three business days (UK MAR). This summary is built from RNS (LSE) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Stephen West

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations4 total
  • ▲
    Executive ChairmanExecutivesRoquefort Therapeutics plc
    36,000 GBP40RNS
    2,400,000 shares@ £0.01563.6% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:5726418
    Canonical exit: 2 Oct 2025 (T+90)
  • ▲
    Executive ChairmanExecutivesRoquefort Therapeutics plc
    10,280 GBP24RNS
    400,000 shares@ £0.025718.8% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:5526077-0
    Canonical exit: 5 May 2025 (T+90)
  • ▲
    Executive ChairmanExecutivesRoquefort Therapeutics plc
    0RNS
    0London Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:4833327
    Canonical exit: 10 Oct 2023 (T+90)
  • ▲
    Executive ChairmanExecutivesRoquefort Therapeutics plc
    9,944 GBP24RNS
    144,117 shares@ £0.06917.6% of flowLondon Stock Exchange (XLON); Main MarketISIN GB00BMDQ2T15RNS:4814253
    Canonical exit: 24 Sept 2023 (T+90)

4 of 4 declarations